



Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014



Published: **January 2014**

Single User PDF: **US\$ 2000**

Corporate User PDF: **US\$ 6000**

**Order this report by calling
+1 888 391 5441 or Send an email
to sales@reportsandreports.com
with your contact details and
questions if any.**



Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014



BUY NOW

Spinal Muscular Atrophy (SMA) Pipeline Review, H1 2014, provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Spinal Muscular Atrophy (SMA) , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Spinal Muscular Atrophy (SMA) . Spinal Muscular Atrophy (SMA) Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Inquiry Before Buying on this Report @

<http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=274913>.

Scope

- A snapshot of the global therapeutic scenario for Spinal Muscular Atrophy (SMA) .
- A review of the Spinal Muscular Atrophy (SMA) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Spinal Muscular Atrophy (SMA) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any.

Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014



Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Spinal Muscular Atrophy (SMA) .
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Spinal Muscular Atrophy (SMA) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Inquire for Discount @ <http://www.reportsnreports.com/contacts/discount.aspx?name=274913>.

List of Tables

Number of Products under Development for Spinal Muscular Atrophy (SMA), H1 2014 10

Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any.

Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014



BUY NOW

List of Tables(cont...)

Number of Products under Development by Companies, H1 2014	13
Number of Products under Investigation by Universities/Institutes, H1 2014	15
Comparative Analysis by Late Stage Development, H1 2014	16
Comparative Analysis by Clinical Stage Development, H1 2014	17
Comparative Analysis by Early Stage Development, H1 2014	18
Products under Development by Companies, H1 2014	19
Products under Investigation by Universities/Institutes, H1 2014	20
Spinal Muscular Atrophy (SMA) - Pipeline by Genzyme Corporation, H1 2014	21
Spinal Muscular Atrophy (SMA) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014	22
Spinal Muscular Atrophy (SMA) - Pipeline by Isis Pharmaceuticals, Inc., H1 2014	23
Spinal Muscular Atrophy (SMA) - Pipeline by Pfizer Inc., H1 2014	24
Spinal Muscular Atrophy (SMA) - Pipeline by Paratek Pharmaceuticals, Inc., H1 2014	25
Spinal Muscular Atrophy (SMA) - Pipeline by Neurotune AG, H1 2014	26
Spinal Muscular Atrophy (SMA) - Pipeline by Trophos SA, H1 2014	27
Spinal Muscular Atrophy (SMA) - Pipeline by Nexgenix Pharmaceuticals, LLC, H1 2014	28
Spinal Muscular Atrophy (SMA) - Pipeline by Genethon, H1 2014	29
Spinal Muscular Atrophy (SMA) - Pipeline by Vybion, Inc., H1 2014	30
Spinal Muscular Atrophy (SMA) - Pipeline by California Stem Cell, Inc., H1 2014	31
Spinal Muscular Atrophy (SMA) - Pipeline by OrphageniX, Inc., H1 2014	32

Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any.

Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014



List of Tables(cont...)

Spinal Muscular Atrophy (SMA) - Pipeline by Retrophin, LLC, H1 2014	33
Spinal Muscular Atrophy (SMA) - Pipeline by Neurodyn Inc., H1 2014	34
Spinal Muscular Atrophy (SMA) - Pipeline by Cellular Biomedicine Group, Inc., H1 2014	35
Spinal Muscular Atrophy (SMA) - Pipeline by gmp-orphan SAS, H1 2014	36
Assessment by Monotherapy Products, H1 2014	37
Assessment by Combination Products, H1 2014	38
Number of Products by Stage and Target, H1 2014	41
Number of Products by Stage and Mechanism of Action, H1 2014	44
Number of Products by Stage and Route of Administration, H1 2014	46
Number of Products by Stage and Molecule Type, H1 2014	49
Number of Products by Stage and Therapeutic Class, H1 2014	52
Spinal Muscular Atrophy (SMA) Therapeutics - Recent Pipeline Updates, H1 2014	83
Spinal Muscular Atrophy (SMA) - Dormant Projects, H1 2014	91

List of Figures

Number of Products under Development for Spinal Muscular Atrophy (SMA), H1 2014	10
Number of Products under Development for Spinal Muscular Atrophy (SMA) - Comparative Analysis, H1 2014	11

Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any.

Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014



BUY NOW

List of Figures(Cont..)

Number of Products under Development by Companies, H1 2014	12
Number of Products under Investigation by Universities/Institutes, H1 2014	14
Comparative Analysis by Late Stage Development, H1 2014	16
Comparative Analysis by Clinical Stage Development, H1 2014	17
Comparative Analysis by Early Stage Products, H1 2014	18
Assessment by Monotherapy Products, H1 2014	37
Number of Products by Top 10 Target, H1 2014	39
Number of Products by Stage and Top 10 Target, H1 2014	40
Number of Products by Top 10 Mechanism of Action, H1 2014	42
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014	43
Number of Products by Top 10 Route of Administration, H1 2014	45
Number of Products by Stage and Top 10 Route of Administration, H1 2014	46
Number of Products by Top 10 Molecule Type, H1 2014	47
Number of Products by Stage and Top 10 Molecule Type, H1 2014	48
Number of Products by Top 10 Therapeutic Class, H1 2014	50
Number of Products by Stage and Top 10 Therapeutic Class, H1 2014	51

Browse more reports on [Pharmaceuticals](#) Market and other [Global Markets Direct](#) Reports.

Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any.